pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Anti-CD19/CD20/CD22 CAR T-cells
drug
save

Anti-CD19/CD20/CD22 CAR T-cells

updated 3mo ago
by National Cancer Institute Center for Cancer Research
community read0 votes

🐶 often sniffed alongside

top 6
  • tagOncology3 co-mentions · 1 sources
  • tagCLL2 co-mentions · 1 sources
  • tagDLBCL1 co-mentions · 1 sources
  • tagCD191 co-mentions · 1 sources
  • tagCD201 co-mentions · 1 sources
  • tagCD221 co-mentions · 1 sources

all catalysts(1)

phase 1 completion · 1
Apr 30, 2026
phase 1 completion
3mo ago
National Cancer Institute Center for Cancer Research — Anti-CD19/CD20/CD22 CAR T-cells (Phase I Trial Completion)
Anti-CD19/CD20/CD22 CAR T-cells
→

News(0)

no news has mentioned this drug yet

Data sources
ClinicalTrials.gov
last refreshed 31m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?